<DOC>
	<DOCNO>NCT02243202</DOCNO>
	<brief_summary>The purpose study compare effect canagliflozin phentermine placebo promote change body weight 26 week period .</brief_summary>
	<brief_title>Effects Co-administration Canagliflozin 300 mg Phentermine 15 mg With Placebo Treatment Non-Diabetic Overweight Obese Participants</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know identity assign treatment ) , placebo-controlled ( inactive substance compare medication test whether medication real effect ) , parallel-group , multicenter study effect canagliflozin phentermine co-administration non-diabetic overweight obese participant . The study conduct 33 week , approximately 344 participant randomly assign 1:1:1:1 ratio one four treatment group : co-administration canagliflozin phentermine , canagliflozin alone , phentermine alone , placebo . All participant also provide diet exercise counsel weight loss ( standardized non-pharmacological therapy ) .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>Must BMI &gt; =30 kg/m2 &lt; 50 kg/m2 screen BMI &gt; =27 kg/m2 &lt; 50 kg/m2 screen presence comorbidity hypertension and/or dyslipidemia Must stable weight , ie , change &lt; =5 % 3 month screen Must agree utilize highly effective method birth control An establish diagnosis diabetes mellitus Has history obesity know secondary cause ( eg , Cushing 's disease/syndrome ) Has history hereditary glucosegalactose malabsorption primary renal glycosuria Myocardial infarction , unstable angina , revascularization procedure , cerebrovascular accident within 12 week screen Has Glycated hemoglobin ( HBA1c ) great equal ( &gt; = ) 65 percent An average 3 seated blood pressure ( BP ) read systolic BP &gt; = 160 mm Hg and/or Diastolic BP &gt; = 100 millimeter mercury screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Phentermine</keyword>
	<keyword>INVOKANAÂ®</keyword>
</DOC>